Lucentis Effective for Proliferative Diabetic Retinopathy

NIH-funded clinical trial marks first major advance in therapy in 40 years.

Abnormal blood vessels bleeding into the center of the eye due to proliferative diabetic retinopathy.

Bethesda, Maryland--(ENEWSPF)--November 16, 2015.  A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) compared Lucentis with a type of laser therapy called panretinal or scatter photocoagulation, which has remained the gold standard for proliferative diabetic retinopathy since the mid-1970s. The findings . . .

First Trustee Forum

First Mayoral Forum

Please follow & like us :)